Literature DB >> 21112268

[Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure].

Mouna Hamouda1, Nasr Ben Dhia, Sabra Aloui, Imene Gorsane, Habib Skhiri, Ameur Frih, Jamel Koobaa, Nabil Driss, Kamel Bouzouita, Mezri Elmay.   

Abstract

OBJECTIVE: To identify the indications for subtotal parathyroidectomy (PTX) in secondary hyperparathyroidism (SHPT) and report postoperative, early and late complications of PTX. PATIENTS AND METHODS: We conducted a retrospective study of subjects with chronic renal failure operated in Tunisian hospitals who received subtotal PTX over 10 years from January 1997 to December 2007. We analyzed the clinical, biological and radiological parameters pre- and postoperatively.
RESULTS: We included 70 patients with average age of 39.4 years, 55.7% men and 44.3% in dialysis for 7.75 ± 4.8 years before PTX. The initial nephropathy was interstitial in 50% of cases. No cases of diabetic nephropathy have been reported. The clinical signs were bone pain (88.6%), muscle pain (85.6%), pruritus (81.4%). Radiological signs of osteitis fibrosa were observed in the majority of patients mainly resorption of extremities (92.9%), thinning of cortical (85.7%) and osteosclerosis (87.1%). The most common indication of PTX (85.7% of cases) was the persistence of serum PTH of more than 800 pg/ml associated with hypercalcemia and/or hyperphosphatemia refractory to medical treatment. A subtotal PTX (3/4 or 7/8) was performed after ultrasound and scintigraphy in the majority of cases. The histology of the parathyroid glands showed diffuse hyperplasia (51.4%), nodular hyperplasia (45.7%) and adenoma (2.8%). The postoperative evolution was marked by an improvement of the clinical and radiological criteria in 80% of cases. A PTH level of less than 15 pg/ml was rarely observed (10% of cases), and a PTH level of more than 300 pg/ml concerned 13% of patients. We noted a low morbidity and mortality (no cases laryngeal paralysis or cervical hematoma).
CONCLUSION: Surgical treatment of SHPT in Tunisia is very effective in our experience. The biological results are comparable to treatment with calcimimetics, not available in Tunisia and whose price is higher. An early treatment of disorders of bone and mineral metabolism should reduce the incidence of SHPT.
Copyright © 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112268     DOI: 10.1016/j.nephro.2010.10.003

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  2 in total

1.  Therapeutic efficacy of two surgical methods on the secondary hyperparathyroidism.

Authors:  Chao Gu; Zhenyu Ye; Yanan Wang; Qin Wang; Jie Qi; Jianhua Chen; Shan Chen; Zekuan Xu
Journal:  Gland Surg       Date:  2020-04

2.  The role of 99mTc-MIBI SPECT-CT in reoperation therapy of persistent hyperparathyroidism patients.

Authors:  Lijie Yin; Dandan Guo; Jie Liu; Jue Yan
Journal:  Open Med (Wars)       Date:  2015-12-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.